The heterogeneity of the glioma subtype glioblastoma multiforme (GBM) challenges effective neuropathological treatment. The reliance on in vitro studies and xenografted animal models to simulate human GBM has proven ineffective. Currently, a dearth of knowledge exists regarding the applicability of cell line biomolecules to the realm of GBM pathogenesis. Our study's objectives were to address this preclinical issue and assess prominin-1, ICAM-1, PARTICLE and GAS5 as potential GBM diagnostic targets. The methodologies included haemoxylin and eosin staining, immunofluorescence, in situ hybridization and quantitative PCR. The findings identified that morphology correlates with malignancy in GBM patient pathology. Immunofluorescence confocal microscopy revealed prominin-1 in pseudo-palisades adjacent to necrotic foci in both animal and human GBM. Evidence is presented for an ICAM-1 association with degenerating vasculature. Significantly elevated nuclear PARTICLE expression from in situ hybridization and quantitative PCR reflected its role as a tumor activator. GAS5 identified within necrotic GBM validated this potential prognostic biomolecule with extended survival. Here we present evidence for the stem cell marker prominin-1 and the chemotherapeutic target ICAM-1 in a glioma animal model and GBM pathology sections from patients that elicited alternative responses to adjuvant chemotherapy. This foremost study introduces the long non-coding RNA PARTICLE into the context of human GBM pathogenesis while substantiating the role of GAS5 as a tumor suppressor. The validation of GBM biomarkers from cellular models contributes to the advancement towards superior detection, therapeutic responders and the ultimate attainment of promising prognoses for this currently incurable brain cancer.

Department of Experimental Neurobiology National Institute of Mental Health Topolová 748 25067 Klecany Czech Republic

Department of Medical Genetics 3rd Faculty of Medicine Charles University Ruská 87 Vinohrady 10000 Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University Ruská 87 Vinohrady 10000 Prague Czech Republic

Department of Pathology University Hospital Královské Vinohrady Šrobárova 50 Vinohrady 10000 Prague Czech Republic

Faculty of Engineering and Science University of Greenwich London Chatham Maritime Kent ME4 4TB UK

Zobrazit více v PubMed

Sofroniew M.V., Vinters H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010;119:7–35. doi: 10.1007/s00401-009-0619-8. PubMed DOI PMC

Balca-Silva J., Matias D., Carmo A.D., Dubios L.G., Concalves A.C., Girao H., Candeo N.H., Correia A.H., De Souza J.N., Sarmento-Ribeiro A.B., et al. Glioblastoma entities express subtle differences in molecular composition and response to treatment. Oncol. Rep. 2017;38:1341–1352. doi: 10.3892/or.2017.5799. PubMed DOI PMC

Araque A., Navarrete M. Glial cells in neuronal network function. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2010;365:2375–2381. doi: 10.1098/rstb.2009.0313. PubMed DOI PMC

MacVicar B.A., Newman E.A. Astrocyte regulation of blood flow in the brain. Cold Spring Harb. Perspect. Biol. 2015;7:a020388. doi: 10.1101/cshperspect.a020388. PubMed DOI PMC

Zong H., Verhaak R.G., Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev. Mol. Diagn. 2012;12:383–394. doi: 10.1586/erm.12.30. PubMed DOI PMC

Quayle S.N., Lee J.Y., Cheung W.T., Ding L., Wiedemeyer R., Dewan R.W., Huang-Hobbs E., Zhuang L., Wilson R.K., Ligon K.L., et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS ONE. 2012;7:e49466. doi: 10.1371/journal.pone.0049466. PubMed DOI PMC

Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. PubMed

Witthayanuwat S., Pesee M., Supaadirek C., Supakalin N., Thamronganantasakul K., Krusun S. Survival Analysis of Glioblastoma Multiforme. Asian Pac. J. Cancer Prev. 2018;19:2613–2617. PubMed PMC

Becker A.P., Sells B.E., Haque S.J., Chakravarti A. Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers. 2021;13:761. doi: 10.3390/cancers13040761. PubMed DOI PMC

Sokratous G., Polyzoidis S., Ashkan K. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme. Hum. Vaccines Immunother. 2017;13:2575–2582. PubMed PMC

Zhu P., Zhu J.J. Tumor treating fields: A novel and effective therapy for glioblastoma: Mechanism, efficacy, safety and future perspectives. Chin. Clin. Oncol. 2017;6:41. doi: 10.21037/cco.2017.06.29. PubMed DOI

Jain K.K. A Critical Overview of Targeted Therapies for Glioblastoma. Front. Oncol. 2018;8:419. PubMed PMC

Wu W., Klockow J.L., Zhang M., Lafortune F., Chang E., Jin L., Wu Y., Daldrup-Link H.E. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol. Res. 2021;171:105780. PubMed PMC

Behling F., Barrantes-Freer A., Skardelly M., Nieser M., Christians A., Stockhammer F., Rohde V., Tatagiba M., Hartmann C., Stadelmann C., et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn. Pathol. 2016;11:55. doi: 10.1186/s13000-016-0506-2. PubMed DOI PMC

Liu S., Shah Z., Sav A., Russo C., Berkovsky S., Qian Y., Coiera E., Di Ieva A. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning. Sci. Rep. 2020;10:7733. PubMed PMC

Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. PubMed DOI PMC

Sledzinska P., Bebyn M.G., Furtak J., Kowalewski J., Lewandowska M.A. Prognostic and Predictive Biomarkers in Gliomas. Int. J. Mol. Sci. 2021;22:10373. doi: 10.3390/ijms221910373. PubMed DOI PMC

Nadeem Abbas M., Kausar S., Wang F., Zhao Y., Cui H. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Cells. 2019;8:350. doi: 10.3390/cells8040350. PubMed DOI PMC

Zhou M., Zhang Z., Zhao H., Bao S., Cheng L., Sun J. An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. Mol. Neurobiol. 2018;55:3684–3697. PubMed

Le B.H., Close R.A. Imaging and Histopathologic Nuances of Epithelioid Glioblastoma. Case Rep. Surg. 2018;2018:1285729. doi: 10.1155/2018/1285729. PubMed DOI PMC

Nelson S.J., Cha S. Imaging glioblastoma multiforme. Cancer J. 2003;9:134–145. doi: 10.1097/00130404-200303000-00009. PubMed DOI

D’Alessio A., Proietti G., Sica G., Scicchitano B.M. Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue. Cancers. 2019;11:469. PubMed PMC

Chen J., Han P., Dahiya S. Glioblastoma: Changing concepts in the WHO CNS5 classification. Indian. J. Pathol. Microbiol. 2022;65((Suppl. S1)):S24–S32. PubMed

Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes. Dev. 2007;21:2683–2710. PubMed

Dobelbower M.C., Burnett Iii O.L., Nordal R.A., Nabors L.B., Markert J.M., Hyatt M.D., Fiveash J.B. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J. Med. Imaging Radiat. Oncol. 2011;55:77–81. doi: 10.1111/j.1754-9485.2010.02232.x. PubMed DOI

Pokorna M., Hudec M., Juříčková I., Vácha M., Polívková Z., Kútna V., Pala J., Ovsepian S.V., Černá M., O’Leary V.B. All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma. Brain Sci. 2021;11:812. doi: 10.3390/brainsci11060812. PubMed DOI PMC

Lee Y.J., Seo H.W., Baek J.H., Lim S.H., Hwang S.G., Kim E.H. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. Sci. Rep. 2020;10:12272. doi: 10.1038/s41598-020-68473-6. PubMed DOI PMC

Piao Y., Henry V., Tiao N., Park S.Y., Martinez-Ledesma J., Dong J.W., Balasubramaniyan V., de Groot J.F. Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget. 2017;8:96970–96983. PubMed PMC

Sener B.B., Yiğit D., Bayraç A.T., Bayraç C. Inhibition of cell migration and invasion by ICAM-1 binding DNA aptamers. Anal. Biochem. 2021;628:114262. doi: 10.1016/j.ab.2021.114262. PubMed DOI

Wang Y., Xin S., Zhang K., Shi R., Bao X. Low GAS5 Levels as a Predictor of Poor Survival in Patients with Lower-Grade Gliomas. J. Oncol. 2019;2019:1785042. doi: 10.1155/2019/1785042. PubMed DOI PMC

Hino O., Klein-Szanto A.J., Freed J.J., Testa J.R., Brown D.Q., Vilensky M., Yeung R.S., Tartof K.D., Knudson A.G. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. Proc. Natl. Acad. Sci. USA. 1993;90:327–331. PubMed PMC

Kutna V., Uttl L., Waltereit R., Krištofiková Z., Kaping D., Petrásek T., Hoschl C., Ovsepian S.V. Tuberous Sclerosis (tsc2+/−) Model Eker Rats Reveals Extensive Neuronal Loss with Microglial Invasion and Vascular Remodeling Related to Brain Neoplasia. Neurotherapeutics. 2020;17:329–339. PubMed PMC

Granak S., Tuckova K., Kutna V., Vojtechova I., Bajkova L., Petrasek T., Ovsepian S.V. Developmental effects of constitutive mTORC1 hyperactivity and environmental enrichment on structural synaptic plasticity and behaviour in a rat model of autism spectrum disorder. Eur. J. Neurosci. 2023;57:17–31. PubMed

Sheehan D.C., Hrapchak B.B. Theory and Practice of Histotechnology. 2nd ed. Battelle Memorial Institute; Columbus, OH, USA: 1987.

O’Leary V.B., Ovsepian S.V., Carrascosa L.G., Buske F.A., Radulovic V., Niyazi M., Moertl S., Trau M., Atkinson M.J., Anastasov N. PARTICLE, a Triplex-Forming Long ncRNA, Regulates Locus-Specific Methylation in Response to Low-Dose Irradiation. Cell Rep. 2015;11:474–485. PubMed

O’Leary V.B., Smida J., Buske F.A., Carrascosa L.G., Azimzadeh O., Maugg D., Hain S., Tapio S., Heidenreich W., Kerr J., et al. PARTICLE triplexes cluster in the tumor suppressor WWOX and may extend throughout the human genome. Sci. Rep. 2017;7:7163. PubMed PMC

Kumar K., Oli A., Hallikeri K., Shilpasree A.S., Goni M. An optimized protocol for total RNA isolation from archived formalin-fixed paraffin-embedded tissues to identify the long non-coding RNA in oral squamous cell carcinomas. MethodsX. 2022;9:101602. PubMed PMC

Brat D.J., Van Meir E.G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Investig. 2004;84:397–405. doi: 10.1038/labinvest.3700070. PubMed DOI

Marzesco A.M., Janich P., Wilsch-Bräuninger M., Dubreuil V., Langenfeld K., Corbeil D., Huttner W.B. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. Pt 13J. Cell Sci. 2005;118:2849–2858. PubMed

O’Leary V.B., Ovsepian S.V., Smida J., Atkinson M.J. PARTICLE—The RNA podium for genomic silencers. J. Cell. Physiol. 2019;234:19464–19470. PubMed

Braga E.A., Fridman M.V., Moscovtsev A.A., Filippova E.A., Dmitriev A.A., Kushlinskii N.E. LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms. Int. J. Mol. Sci. 2020;21:8855. PubMed PMC

Ghafouri-Fard S., Fathi M., Zhai T., Taheri M., Dong P. LncRNAs: Novel Biomarkers for Pancreatic Cancer. Biomolecules. 2021;11:1665. PubMed PMC

Fang X., Zhong G., Wang Y., Lin Z., Lin R., Yao T. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis. 2020;11:531. PubMed PMC

Zhao X., Wang P., Liu J., Zheng J., Liu Y., Chen J., Xue Y. Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222. Mol. Ther. 2015;23:1899–1911. PubMed PMC

Karami A., Hossienpour M., Mohammadi Noori E., Rahpyma M., Najafi K., Kiani A. Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. Nutr. Cancer. 2022;74:1299–1307. doi: 10.1080/01635581.2021.1952441. PubMed DOI

Oliva M.A., Staffieri S., Sanchez M., Arcella A. Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy. Molecules. 2022;27:8335. doi: 10.3390/molecules27238335. PubMed DOI PMC

Yam N., Levin J., Bao Z., Qian W., Levin V.A. Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells. Oncotarget. 2020;11:3933–3942. PubMed PMC

Yeung R.S. Lessons from the Eker rat model: From cage to bedside. Curr. Mol. Med. 2004;4:799–806. doi: 10.2174/1566524043359791. PubMed DOI

Lukina M., Yashin K., Kiseleva E.E., Alekseeva A., Dudenkova V., Zagaynova E.V., Bederina E., Medyanic I., Becker W., Mishra D., et al. Label-Free Macroscopic Fluorescence Lifetime Imaging of Brain Tumors. Front. Oncol. 2021;11:666059. doi: 10.3389/fonc.2021.666059. PubMed DOI PMC

Dajani S., Hill V.B., Kalapurakal J.A., Horbinski C.M., Nesbit E.G., Sachdev S., Yalamanchili A., Thomas T.O. Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. J. Clin. Med. 2022;11:5961. doi: 10.3390/jcm11195961. PubMed DOI PMC

Rong Y., Durden D.L., Van Meir E.G., Brat D.J. ‘Pseudopalisading’ necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. 2006;65:529–539. doi: 10.1097/00005072-200606000-00001. PubMed DOI

Zagzag D., Amirnovin R., Greco M.A., Yee H., Holash J., Wiegand S.J., Zabski S., Yancopoulos G.D., Grumet M. Vascular apoptosis and involution in gliomas precede neovascularization: A novel concept for glioma growth and angiogenesis. Lab. Investig. 2000;80:837–849. doi: 10.1038/labinvest.3780088. PubMed DOI

Christensen K., Schroder H.D., Kristensen B.W. CD133 identifies perivascular niches in grade II-IV astrocytomas. J. Neurooncol. 2008;90:157–170. PubMed

Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. PubMed

Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. PubMed

Panizza E., Regalado B.D., Wang F., Nakano I., Vacanti N.M., Cerione R.A., Antonyak M.A. Proteomic analysis reveals microvesicles containing NAMPT as mediators of radioresistance in glioma. Life Sci. Alliance. 2023;6:e202201680. doi: 10.26508/lsa.202201680. PubMed DOI PMC

El Hallani S., Boisselier B., Peglion F., Rousseau A., Colin C., Idbaih A., Marie Y., Mokhtari K., Thomas J.L., Eichmann A., et al. A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Pt 4Brain. 2010;133:973–982. PubMed PMC

Minajeva A., Kase M., Saretok M., Adamson-Raieste A., Kase S., Niinepuu K., Vardja M., Asser T., Jaal J. Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients. Neurosci. J. 2017;2017:5629563. PubMed PMC

Winning S., Splettstoesser F., Fandrey J., Frede S. Acute hypoxia induces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: The role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-kappa B. J. Immunol. 2010;185:1786–1793. doi: 10.4049/jimmunol.0903244. PubMed DOI

Stackhouse C.T., Gillespie G.Y., Willey C.D. Exploring the Roles of lncRNAs in GBM Pathophysiology and Their Therapeutic Potential. Cells. 2020;9:2369. PubMed PMC

Rezaei O., Tamizkar K.H., Sharifi G., Taheri M., Ghafouri-Fard S. Emerging Role of Long Non-Coding RNAs in the Pathobiology of Glioblastoma. Front. Oncol. 2020;10:625884. PubMed PMC

Yadav B., Pal S., Rubstov Y., Goel A., Garg M., Pavlyukov M., Pandey A.K. LncRNAs associated with glioblastoma: From transcriptional noise to novel regulators with a promising role in therapeutics. Mol. Ther. Nucleic Acids. 2021;24:728–742. doi: 10.1016/j.omtn.2021.03.018. PubMed DOI PMC

Toraih E.A., Alghamdi S.A., El-Wazir A., Hosny M.M., Hussein M.H., Khashana M.S., Fawzy M.S. Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors. PLoS ONE. 2018;13:e0198231. doi: 10.1371/journal.pone.0198231. PubMed DOI PMC

Shen J., Hodges T.R., Song R., Gong Y., Calin G.A., Heimberger A.B., Zhao H. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol. Carcinog. 2018;57:137–141. doi: 10.1002/mc.22739. PubMed DOI

Chaudhary R. Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis. Heliyon. 2021;7:e06502. doi: 10.1016/j.heliyon.2021.e06502. PubMed DOI PMC

lncRNA Biomarkers of Glioblastoma Multiforme